News

Multiple Sclerosis Discovery Forum Review Article on EAE Models

2012-05-02T13:04:27Z

The Multiple Sclerosis Discovery Forum publishes a thorough review article by Alla Katsnelson, 'Animal Arsenal: An overview of animal models that mimic key aspects of MS'

The article highlights key factors to be considered by Pharma companies persuing MS drug development, and underpins the Aquila BioMedical in-vitro T cell service using MBP-Tracker T cells tailored to mimic the in vivo MS pathophysiology, with studies designed to generate high value data from compound screening. The most promising drug candidates can then be selected for testing in the adoptive transfer MBP-Tracker in-vivo model.

Aquila featured in Young Company Finance Scotland newsletter

2012-04-19T07:48:59Z

An article was published on Aquila BioMedical in the April issue (No 160) of Young Company Finance Scotland, covering the SMART:Scotland award and details on the application of the MBP-Tracker technology to preclinical research in MS and autoimmune disease.

Director of Aquila to judge in 2012 Venture Programme competition

2012-03-21T09:37:33Z

Dr Howard Marriage, Director of Aquila BioMedical, will join the panel of judges assessing the ideas of young researchers at the University of Dundee in the 2012 Venture Programme competition. Candidates will compete for up to £5000 seed money to turn their ideas into commercial applications. The event intends to develop the entrepreneurial skills of research postgraduates and early career researchers, enhancing the Scottish scientific community.

SMi Pain Therapeutics Conference

2012-03-19T12:26:56Z

Aquila BioMedical will attend the SMi's 12th Annual Pain Therapeutics Conference, London, UK, 21st-22nd May 2012 (www.pain-therapeutics.co.uk). Industry experts will meet to discuss the latest advances in analgesic drug development. We are looking forward to what promises to be an exciting and educational event. Please contact us if you would like to arrange to meet at the conference.

Scottish Enterprise Innovation Support

2012-01-30T11:29:21Z

Scottish Enterprise offers Innovation Support for the Development of Aquila BioMedical's Contract Pain Services. This will allow Aquila to progress in its expansion of services, and accelerate growth.

SMART:SCOTLAND Award

2012-01-03T11:21:46Z

Aquila BioMedical is very pleased to announce the receipt of SMART:SCOTLAND funding for the purpose of developing the innovative MBP-tracker model. This technology will provide opportunity to the Pharmaceutical Industry to gain access to high value mechanism of action tools which will be relevant to the investigation of a range of T cell mediated autoimmune diseases, including Multiple Sclerosis. We look forward to discussing this with interested parties.

Chief Operating Officer Appointed

2011-12-05T14:11:14Z

Aquila BioMedical appoints COO to drive leadership, quality and rapid growth of it's service offerings. The COO brings a wealth of experience from over 12 years in contract Preclinical GLP services. The chairman of Aquila states 'We are very excited to have our new COO on board and anticipate that the experience and contacts that come from this appointment will be critical for Aquila's future success. Furthermore, this appointment will accelerate Aquila's expansion into other service areas.' Feel free to contact us for more information on our future plans.

Aquila R&D Strategy Announced

2011-11-30T09:21:42Z

Today Aquila announces its core Research and Development Strategy in the areas of MS, Autoimmune disease, Inflammation and Pain which will underpin the focus of the company over the next year. This will provide a unique service platform for the development of compounds within these therapeutic areas.

New Aquila Website Launch

2011-11-23T13:43:31Z

We are delighted to launch our new website that we have been working hard on over the last couple of months. Feel free to let us know what you think.